Ann: Quarterly Cashflow Report, page-9

With less spending expected I would also assume that a new trail is not required either.

Not sure that is the case @Joelsmith2452 ... but I guess we will know soon enough ?

I have noticed that under this section of the quarterlies,

9. Estimated cash outflows for next quarter

that under anticipated

"Product manufacturing and operating costs "

we have gone down from:

$1,000,000 in 30 June 2019

to $700,000 31 Oct 2019

to $600,000 31 Dec 2019

Either our production costs per unit have decreased due to increased production volumes in the same production runs ? .... or we are making less products for sale ? Let's hope it is the former ?

I am happy that they are now breaking down VivaGel® BV revenue instead of it all being lumped into one amount in "Receipts from Customers" as was how they reported previously, IMO they are perhaps listening in some ways ?

Product supply and royalty receipts for VivaGel® BV totalled $0.9 million for the quarter.

Otherwise basically things we already knew - bring on the DEP Docetaxel results I say